Literature DB >> 30674724

Frequent clonal relations between metastases and non-index prostate cancer lesions.

Jeroen Kneppers1,2, Oscar Krijgsman2,3, Monique Melis4, Jeroen de Jong2,5, Daniel S Peeper2,3, Elise Bekers5, Henk G van der Poel6, Wilbert Zwart1,2,7, Andries M Bergman1,8.   

Abstract

Primary prostate cancer lesions are clonally heterogeneous and often arise independently. In contrast, metastases were reported to share a monoclonal background. Because prostate cancer mortality is the consequence of distant metastases, prevention of metastatic outgrowth by primary tumor ablation is the main focus of treatment for localized disease. Focal therapy is targeted ablation of the primary index lesion, but it is unclear whether remaining primary lesions metastasize at a later stage. In this study, we compared copy number aberration profiles of primary prostate cancer lesions with matching pelvic lymph node metastases of 30 patients to establish clonality between a lymph node metastasis and multiple primary lesions within the same patient. Interestingly, in 23.3% of the cases, the regional metastasis was not clonally linked to the index primary lesion. These findings suggest that focal ablation of only the index lesion is potentially an undertreatment of a significant proportion of prostate cancer patients.

Entities:  

Keywords:  Genetics; Oncology; Prostate cancer

Year:  2019        PMID: 30674724      PMCID: PMC6413780          DOI: 10.1172/jci.insight.124756

Source DB:  PubMed          Journal:  JCI Insight        ISSN: 2379-3708


  9 in total

Review 1.  Cellular and Molecular Mechanisms Underlying Prostate Cancer Development: Therapeutic Implications.

Authors:  Ugo Testa; Germana Castelli; Elvira Pelosi
Journal:  Medicines (Basel)       Date:  2019-07-30

Review 2.  Genomic and phenotypic heterogeneity in prostate cancer.

Authors:  Michael C Haffner; Wilbert Zwart; Martine P Roudier; Lawrence D True; William G Nelson; Jonathan I Epstein; Angelo M De Marzo; Peter S Nelson; Srinivasan Yegnasubramanian
Journal:  Nat Rev Urol       Date:  2020-12-16       Impact factor: 14.432

3.  The SAFE Pilot Trial-SAlvage Focal Irreversible Electroporation-For Recurrent Localized Prostate Cancer: Rationale and Study Protocol.

Authors:  Giancarlo Marra; Taimur T Shah; Daniele D'Agate; Alessandro Marquis; Giorgio Calleris; Luca Lunelli; Claudia Filippini; Marco Oderda; Marco Gatti; Massimo Valerio; Rafael Sanchez-Salas; Alberto Bossi; Juan Gomez-Rivas; Francesca Conte; Desiree Deandreis; Olivier Cussenot; Umberto Ricardi; Paolo Gontero
Journal:  Front Surg       Date:  2022-06-07

4.  Comparison of a Personalized Prostate Biopsy Pattern With Traditional Transrectal Prostate Biopsy: Different Cancer Detection Rate.

Authors:  Xin Jiang; Sifeng Qu; Yaofeng Zhu; Shuo Wang; Haoyu Sun; Hu Guo; Benkang Shi; Shouzhen Chen
Journal:  Front Cell Dev Biol       Date:  2022-05-04

5.  Prostate cancer evolution from multilineage primary to single lineage metastases with implications for liquid biopsy.

Authors:  D J Woodcock; E Riabchenko; S Taavitsainen; M Kankainen; G Gundem; D S Brewer; P Ellonen; M Lepistö; Y A Golubeva; A C Warner; T Tolonen; J Jasu; W B Isaacs; M R Emmert-Buck; M Nykter; T Visakorpi; G S Bova; D C Wedge
Journal:  Nat Commun       Date:  2020-10-08       Impact factor: 14.919

6.  Genomic Landscape Alterations in Primary Tumor and Matched Lymph Node Metastasis in Hormone-Naïve Prostate Cancer Patients.

Authors:  Giorgio Ivan Russo; Paolo Bonacci; Dalida Bivona; Grete Francesca Privitera; Giuseppe Broggi; Rosario Caltabiano; Jessica Vella; Arturo Lo Giudice; Maria Giovanna Asmundo; Sebastiano Cimino; Giuseppe Morgia; Stefania Stefani; Nicolò Musso
Journal:  Cancers (Basel)       Date:  2022-08-30       Impact factor: 6.575

7.  Focal therapy for prostate cancer - index lesion treatment vs. hemiablation. A matter of definition.

Authors:  Armando Stabile; Marco Moschini; Francesco Montorsi; Xavier Cathelineau; Rafael Sanchez-Salas
Journal:  Int Braz J Urol       Date:  2019 Sep-Oct       Impact factor: 3.050

8.  Collision tumors revealed by prospectively assessing subtype-defining molecular alterations in 904 individual prostate cancer foci.

Authors:  Jacqueline Fontugne; Peter Y Cai; Hussein Alnajar; Bhavneet Bhinder; Kyung Park; Huihui Ye; Shaham Beg; Verena Sailer; Javed Siddiqui; Mirjam Blattner-Johnson; Jaclyn A Croyle; Zohal Noorzad; Carla Calagua; Theresa Y MacDonald; Ulrika Axcrona; Mari Bogaard; Karol Axcrona; Douglas S Scherr; Martin G Sanda; Bjarne Johannessen; Arul M Chinnaiyan; Olivier Elemento; Rolf I Skotheim; Mark A Rubin; Christopher E Barbieri; Juan Miguel Mosquera
Journal:  JCI Insight       Date:  2022-02-22

9.  The Precision Prostatectomy: an IDEAL Stage 0, 1 and 2a Study.

Authors:  Akshay Sood; Wooju Jeong; Kanika Taneja; Firas Abdollah; Isaac Palma-Zamora; Sohrab Arora; Nilesh Gupta; Mani Menon
Journal:  BMJ Surg Interv Health Technol       Date:  2019-08-19
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.